A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
Although they may not be associated with a particular company, generic drugs are usually subject to government regulations in the countries where they are dispensed. They are labeled with the name of the manufacturer and a generic nonproprietary name such as theUnited States Adopted Name or international nonproprietary name of the drug. A generic drug must contain the same active ingredientsas the original brand-name formulation. The U.S. Food and Drug Administration (FDA) requires that generics be identical to, or within an acceptable bioequivalent range of, their brand-name counterparts with respect to pharmacokinetic and pharmacodynamic properties.(The FDA’s use of the word “identical” is a legal interpretation, not literal.)
Biopharmaceuticals such as monoclonal antibodies differ biologically from small molecule drugs. Generic versions of these drugs, known as biosimilars, are typically regulated under an extended set of rules.
In most cases, generic products become available after the patent protections afforded to a drug’s original developer expire. Once generic drugs enter the market, competition often leads to substantially lower prices for both the original brand-name product and its generic equivalents. In most countries, patents give 20 years of protection. However, many countries and regions, such as the European Union and the United States, may grant up to five years of additional protection (“patent term restoration”) if manufacturers meet specific goals, such as conducting clinical trials for pediatric patients. Manufacturers, wholesalers, insurers, and drugstores can each increase prices at various stages of production and distribution.
In 2014, according to an analysis by the Generic Pharmaceutical Association, generic drugs accounted for 88% of the 4.3 billion prescriptions filled in the United States.:
Generic drug names are constructed using standardized affixes that distinguish drugs between and within classes and suggest their action.
When a pharmaceutical company first markets a drug, it is usually under a patent that, until it expires, the company can use to exclude competitors by suing them for patent infringement. Pharmaceutical companies that develop new drugs generally only invest in drug candidates with strong patent protection as a strategy to recoup their costs todevelop the drug (include the costs of the drug candidates that fail) and to make a profit. The average cost to a brand-name company of discovering, testing, and obtaining regulatory approval for a new drug, with a new chemical entity, was estimated to be as much as $800 million in 2003 and $2.6 billion in 2014. Drug companies that bring new products have several product line extension strategies they use to extend their exclusivity, some of which are seen as gaming the system and referred to by critics as “evergreening“, but at some point there is no patent protection available. For as long as a drug patent lasts, a brand-name company enjoys a period of market exclusivity, ormonopoly, in which the company is able to set the price of the drug at a level that maximizes profit. This profit often greatly exceeds the development and production costs of the drug, allowing the company to offset the cost of research and development of other drugs that are not profitable or do not pass clinical trials.
Large pharmaceutical companies often spend millions of dollars protecting their patents from generic competition. Apart from litigation, they may reformulate a drug or license a subsidiary (or another company) to sell generics under the original patent. Generics sold under license from the patent holder are known as authorized generics.
Generic drugs are usually sold for significantly lower prices than their branded equivalents and at lower profit margins. One reason for this is that competition increases among producers when a drug is no longer protected by patents. Generic companies incur fewer costs in creating generic drugs—only the cost of manufacturing, without the costs ofdrug discovery and drug development—and are therefore able to maintain profitability at a lower price. The prices are often low enough for users in less-prosperous countries to afford them. For example, Thailand has imported millions of doses of a generic version of the blood-thinning drug Plavix (used to help prevent heart attacks) from India, the leading manufacturer of generic drugs, at a cost of 3 US cents per dose.
Generic drug companies may also receive the benefit of the previous marketing efforts of the brand-name company, including advertising, presentations by drug representatives, and distribution of free samples. Many drugs introduced by generic manufacturers have already been on the market for a decade or more and may already be well known to patients and providers, although often under their branded name.
In the United Kingdom, generic drug pricing is controlled by the government’s reimbursement rate. The price paid by pharmacists and doctors is determined mainly by the number of license holders, the sales value of the original brand, and the ease of manufacture. A typical price decay graph will show a “scalloped” curve, which usually starts at the brand-name price on the day of generic launch and then falls as competition intensifies. After some years, the graph typically flattens out at approximately 20% of the original brand price. In about 20% of cases, the price “bounces”: Some license holders withdraw from the market when the selling price dips below their cost of goods, and the price then rises for a while until the license holders re-enter the market with new stock.
Bioequivalence does not mean generic drugs must be exactly the same as the brand-name product (“pharmaceutical equivalent”). Chemical differences may exist; a different saltor ester may be used, for instance. However, the therapeutic effect of the drug must be the same (“pharmaceutical alternative”). Most small molecule drugs are accepted as bioequivalent if their pharmacokinetic parameters of AUC (area under concentration) and Cmax (maximum concentration) are within a 90% confidence interval of 80–125%; most approved generics are well within this limit. For more complex products—such as inhalers, patch delivery systems, liposomal preparations, or biosimilar drugs—demonstrating pharmacodynamic or clinical equivalence is more challenging.
Enacted in 1984, the Drug Price Competition and Patent Term Restoration Act, informally known as the Hatch-Waxman Act, standardized procedures for recognition of generic drugs. In 2007, the FDA launched the Generic Initiative for Value and Efficiency (GIVE): an effort to modernize and streamline the generic drug approval process, and to increase the number and variety of generic products available.
Before a company can market a generic drug, it needs to file an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration, seeking to demonstrate therapeutic equivalence to a previously approved “reference-listed drug” and proving that it can manufacture the drug safely and consistently. For an ANDA to be approved, the FDA requires the bioequivalence of a generic drug to be between 80% and 125% of the innovator product. (This range is part of a statistical calculation, and does not mean that generic drugs are allowed to differ from their brand-name counterparts by up to 25 percent.) The FDA evaluated 2,070 studies conducted between 1996 and 2007 that compared the absorption of brand-name and generic drugs into a person’s body. The average difference in absorption between the generic and the brand-name drug was 3.5 percent, comparable to the difference between two batches of a brand-name drug. Generic versions of biologic drugs, or biosimilars, require clinical trials forimmunogenicity in addition to tests establishing bioequivalency. These products cannot be entirely identical because of batch-to-batch variability and their biological nature, and they are subject to extra rules.
When an application is approved, the FDA adds the generic drug to its Approved Drug Products with Therapeutic Equivalence Evaluations list and annotates the list to show equivalence between the reference-listed drug and the generic. The FDA also recognizes drugs that use the same ingredients with different bioavailability, and divides them into therapeutic equivalence groups. For example, as of 2006, diltiazem hydrochloride had four equivalence groups, all using the same active ingredient, but considered equivalent only within each group.
In order to start selling a drug promptly after the patent on innovator drug expires, a generic company has to file its ANDA well before the patent expires. This puts the generic company at risk of being sued for patent infringement, since the act of filing the ANDA is considered “constructive infringement” of the patent. In order to incentivize generic companies to take that risk the Hatch-Waxman act granted a 180-day administrative exclusivity period to generic drug manufacturers who are the first to file an ANDA.
When faced with patent litigation from the drug innovator, generic companies will often counter-sue, challenging the validity of the patent. Like any litigation between private parties, the innovator and generic companies may choose to settle the litigation. Some of these settlement agreements have been stuck down by courts when they took the form of reverse payment patent settlement agreements, in which the generic company basically accepts a payment to drop the litigation, delaying the introduction of the generic product and frustrating the purpose of the Hatch-Waxman Act.
Innovator companies sometimes try to maintain some of the revenue from their drug after patents expire by allowing another company to sell an authorized generic; a 2011 FTC report found that consumers benefitted from lower costs when an authorized generic was introduced during the 180 exclusivity period, as it created competition.
Innovator companies may also present arguments to the FDA that the ANDA should not be accepted by filing a “citizen petition” with the FDA. Citizen petitions are part of the basic law governing everything the FDA does – at any time, any “interested person” can request that the FDA “issue, amend, or revoke a regulation or order,” or “take or refrain from taking any other form of administrative action.” Originally there was no deadline by which the FDA had to respond to citizen petitions filed to protest ANDAs, leading to significant delays in approving generics. In 2007 the law was amended to include a new section, Section 505(q), in the part of the federal code created by the Hatch-Waxman Act; this section said that the FDA could not delay approving an ANDA due to concerns raised in a citizen petition unless the delay was “necessary to protect public health”; it also mandated that the FDA needed to respond to a petition within 180 days – this was shorted to 150 days in a 2011 amendment. In 2014 the FDA issued guidance to industry about submitting citizen petitions and how it would consider them.
A series of scandals around the approval of generic drugs in the late 1980s shook public confidence in generic drugs; there were several instances in which companies obtained bioequivalence data fraudulently, by using the branded drug in their tests instead of their own product, and a congressional investigation found corruption at the FDA, where employees were accepting bribes to approve some generic companies’ applications and delaying or denying others.
Some generic drugs are viewed with suspicion by doctors. For example, warfarin (Coumadin) has a narrow therapeutic window and requires frequent blood tests to make sure patients do not have a subtherapeutic or a toxic level. A study performed in Ontario showed that replacing Coumadin with generic warfarin was safe, but many physicians are not comfortable with their patients taking branded generic equivalents. In some countries (for example, Australia) where a drug is prescribed under more than one brand name, doctors may choose not to allow pharmacists to substitute a brand different from the one prescribed unless the consumer requests it.
In 2007, North Carolina Public Radio‘s The People’s Pharmacy began reporting on consumers’ complaints that generic versions of bupropion (Wellbutrin) were yielding unexpected effects. Subsequently, Impax Laboratories‘s 300 mg extended-release tablets, marketed by Teva Pharmaceutical Industries, were withdrawn from the US market after the FDA determined in 2012 that they were not bioequivalent.
Two women, each claiming to have suffered severe medical complications from a generic version of metoclopramide, lost their Supreme Court appeal on June 23, 2011. In a 5-4 ruling in PLIVA, Inc. v. Mensing, in which the court held that generic companies cannot be held liable for information, or the lack of information, on the originator’s label.
The Indian government began encouraging more drug manufacturing by Indian companies in the early 1960s, and with the Patents Act in 1970. The Patents Act removed composition patents for foods and drugs, and though it kept process patents, these were shortened to a period of five to seven years. The resulting lack of patent protection created a niche in both the Indian and global markets that Indian companies filled by reverse-engineering new processes for manufacturing low-cost drugs. Mumbai, India headquartered Sun Pharmaceutical’s consolidated revenues for the 12 months ending March 2015 are US$4.5 billion.
Generic drug production is a large part of the pharmaceutical industry in China. Western observers have said that China lacks administrative protection for patents. However, entry to the World Trade Organization has brought a stronger patent system.
- Anti-Counterfeiting Trade Agreement#Criminalising generic medicine (ACTA)
- Bayh–Dole Act
- Chemical patents
- Generic brand
- International Nonproprietary Name
- Inverse benefit law
- Prescription costs
- Research exemption
- SOPA#Protection against counterfeit drugs
- Trans-Pacific Partnership Intellectual Property Provisions
- Transatlantic Trade and Investment Partnership
- “Generic Drugs”, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- www.medterms.com: definition of generic drug
- Definition of generic drug
- “Food & Drug Administration, Generic Drugs: Questions and Answers”. Food and Drug Administration. January 12, 2010. Retrieved 2010-02-03.
- 35 U.S.C. § 154(a)(2)
- “Pediatric Research Equity Act of 2007” (PDF).
- “An insider’s view of generic-drug pricing”. Los Angeles Times. March 25, 2013.
- “Generic Drug Savings in the U.S.” (PDF). Washington, DC: Generic Pharmaceutical Association (GPhA). 2015. Retrieved 16 June 2016.
- Gupta, H; Kumar, S; Roy, SK; Gaud, RS (January 2010). “Patent protection strategies.”. Journal of pharmacy & bioallied sciences. 2 (1): 2–7. doi:10.4103/0975-7406.62694. PMC . PMID 21814422.
- Frakt, Austin (28 September 2015). “How Patent Law Can Block Even Lifesaving Drugs”. The New York Times.
- DiMasi J.A.; et al. (2003). “The price of innovation: new estimates of drug development cost” (PDF). Journal of Health Economics. 22: 151–185. doi:10.1016/s0167-6296(02)00126-1.
- Tufts Center for the Study of Drug Development (November 18, 2014). “Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion”. Tufts University.
- “Authorized Generics”. Generic Pharmaceutical Association (GPhA). 2008. Archived from the original on 2008-05-29. Retrieved 2008-06-16.
- “Savings From Generic Drugs Purchased at Retail Pharmacies”. Food and Drug Administration. April 2004. Archived from the original on 2008-02-23. Retrieved2008-07-11.
- The role of reverse engineering in the development of generic formulations
- Benson, Mike (February 20, 2015). “What it takes to be called ‘big pharma’ – Market Realist”. Market Realist.
- “Thailand to import generic version of heart drug Plavix from India”. Forbes. 2007-08-22. Retrieved 2008-10-13. Forbes.com
- “Price decay after loss of brand exclusivity (patent expiry) and generic launch”. PharmaPhorum. 4 Apr 2012.
- “Guessing at prices means losing money”. Generics Bulletin. 8 Sep 2006.[full citation needed]
- “Getting to the bottom of ‘bouncing’ price”. Generics Bulletin. 16 Feb 2007.[full citation needed]
- Boehm, Garth; Yao, Lixin; Han, Liang; Zheng, Qiang (September 2013).“Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984”. Acta Pharmaceutica Sinica B. 3 (5): 297–311. doi:10.1016/j.apsb.2013.07.004.
- WHO Technical Report Series No. 937: Annex 7 (pdf) WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO Technical Report Series No. 937): Annex 7 – Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability, May 2006. Accessed 2008-06-15
- Food and Drug Administration, Department of Health and Human Services: Code of Federal Regulations 320 Title 21, Volume 5, Revised as of April 1, 2008 CFR 320 21/5, Revised as of April 1, 2008. Accessed 2008-06-15
- Health Canada, Drugs and Health Products, Bioavailability and Bioequivalence Health Canada, Guidance Documents. Accessed 2008-06-15
- EudraLex – The Rules Governing Medicinal Products in the European UnionEudraLex. Accessed 2008-06-15
- European Medicines Agency EMEA. Accessed 2008-06-15
- Japan, National Institute for Health Sciences, Division of Drugs Guidances Japan, NIHS, Division of Drugs. Accessed 2008-06-15
- Davit, BM; Nwakama PE; Buehler GJ; Conner Dp; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J (2009). “Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.”. Annals of Pharmacology. 43: 1583–97. doi:10.1345/aph.1m141.
- Warren, JB (2013). “Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?”. Br J Clin Pharmacol. 75 (1): 7–14. doi:10.1111/j.1365-2125.2012.04323.x.PMC . PMID 22574725.
- “Generic Initiative for Value and Efficiency (GIVE)”. FDA. October 4, 2007. Retrieved2008-06-15.
- Mossinghoff GJ (1999). “Overview of the Hatch-Waxman Act and its impact on the drug development process” (PDF). Food Drug Law J. 54: 187–94. PMID 11758572.
- “Orange Book Annual Preface, Statistical Criteria for Bioequivalence”. Approved Drug Products with Therapeutic Equivalence Evaluations 29th Edition. U.S. Food and Drug Administration Center for Drug Evaluation and Research. 2009-06-18. Retrieved2009-08-10.
- “Facts about Generic Drugs”. Food and Drug Administration.
- Davit; et al. (2009). “Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration”. Ann Pharmacother. 43 (10): 1583–97. doi:10.1345/aph.1m141.
- Calo-Fernández, Bruno; Martínez-Hurtado J L (2012-12-12). “Biosimilars: Company Strategies to Capture Value from the Biologics Market”. Pharmaceuticals. 5 (12): 1393–1408. doi:10.3390/ph5121393. PMC . PMID 24281342. Retrieved2012-12-12.
- Approved Drug Products with Therapeutic Equivalence Evaluations, Preface. – an explanation of FDA terms and procedures
- “Guidance for Industry: 180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act” (PDF). FDA, Center for Drug Evaluation and Research (CDER). June 1998. Retrieved August 24, 2009.
- “Paragraph IV Drug Product Applications: Generic Drug Patent Challenge Notifications”. FDA, Office of Generic Drugs (OGD). 2008-06-11. Retrieved 2008-06-16.
-  Brisol-Myers Squibb press release on successful defense of Plavix patentArchived October 16, 2007, at the Wayback Machine.
-  Apotex press release on successful challenge of Norvasc patent Archived June 23, 2007, at the Wayback Machine.
-  Apotex press release on successful challenge of Paxil patent Archived August 7, 2007, at the Wayback Machine.
- Einer Elhauge & Alex Krueger. “Solving the Patent Settlement Puzzle”. Texas Law Review. Retrieved 29 September 2012.
- Wyatt, Edward (17 June 2013). “Supreme Court Lets Regulators Sue Over Generic Drug Deals”. New York Times. Retrieved 9 May 2015.
- “#223: Authorized Generic Drug Study”. FTC. August 2011.
- “Authorized Generic Drugs: Short-Term Effects and Long-Term ImpactAuthorized Generic Drugs: Short-Term Effects and Long-Term Impact” (PDF). FTC. August 2011.
- Carrier, Michael A.; Wander, Daryl (2012). “Citizen Petitions: An Empirical Study”(PDF). Cardozo Law Review. 34: 249–293.
- Silber, Seth; Lutinski, Jonathan; Taylon, Rachel (January 2012). “Abuse of the FDA Citizen Petition Process: Ripe for Antitrust Challenge?” (PDF). Antitrust Health Care Chronicle.
- Brown, June Gibbs (July 17, 1998). “Review of the Food and Drug Administration’s Citizen Petition Process” (PDF). US Department of Health and Human Services, Office of the Inspector General.
- “Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry” (PDF). FDA. November 2014.
- Strickland, Carol (15 October 1989). “Bolar: A Drug Company Under Siege”. The New York Times.
- Freudenheim, Milt (10 September 1989). “Exposing the F.D.A.”. New York Times.
- Andrews, Edmund L. (31 July 1989). “F.D.A. Inquiry on Generic Drugs Focuses on Changes in Ingredients”. The New York Times.
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, Crowther MA, Bates SM, Ginsberg JS (2005). “Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials”. Ann Pharmacother. 39(7–8): 1188–93. doi:10.1345/aph.1G003. PMID 15914517.
- Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, Crowther M, Bates SM, Ginsberg JS (2005). “Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians” (PDF). Can J Clin Pharmacol. 12 (3): e229–39. PMID 16278495.
- “Generic medicines training kit: safe and appropriate use of generic medicines”.Pharmaceutical Society of Australia Competency Standards for Pharmacists in Australia 2003. National Prescribing Service Limited (NPS). 2003-07-09. Retrieved2010-01-24.“Prescribers may disallow brand switching by ticking the relevant box on the PBS prescription form”
- “Drug Tests: Wellbutrin vs. Generic Bupropion”. 2012-12-06. Retrieved 2013-04-20.
- Healy, Melissa (2012-10-05). “Generic antidepressant pulled from U.S. shelves after FDA finding”. Los Angeles Times. Retrieved 2013-04-20.
- “FDA Update: Budeprion XL 300 mg Not Therapeutically Equivalent to Wellbutrin XL 300 mg”. U.S. Food and Drug Administration. 2012-10-03. Retrieved 2013-04-20.
- Scotus Blog: PLIVA, Inc. v. Mensing
- Supreme Court of the United States 564 PLIVA, Inc. v. Mensing U. S. ____ (2011)
- Adam Liptak for the New York Times. June 23, 2011 Drug Makers Win Two Supreme Court Decisions
- Steven Casey for Law360. October 24, 2012 Generic Pharmaceutical Liability: Challenges And Changes
- Mears, B (2011-06-23). “High Court sides with generic drug makers in narrow ruling”.CNN. Retrieved 2013-01-01.
- http://www.ircc.iitb.ac.in/IPcourse/patent.html Archived April 30, 2010, at theWayback Machine.
- George T. Haley; Usha C.V. Haley (2012). “The effects of patent-law changes on innovation: The case of India’s pharmaceutical industry”. Technological Forecasting and Social Change. 79 (4): 607–619. doi:10.1016/j.techfore.2011.05.012.
- “Market report on The Top 100 Manufacturers Of Generic Pharmaceuticals Worldwide now available”. Market Report. Market Reports World. 1 March 2016. Retrieved 21 July2016.
- “China’s Pharmaceutical Industry Lacks Innovation, Lags Behind”, China Watch, Washington, D.C., United States: Worldwatch Institute, worldwatch.org, retrieved Jan 3,2012
- United States Adopted Names Program, generic drug naming process, lists of adopted names
- USFDA, Office of Generic Drugs
- UK Department of Health, generic drugs
- The Medical Letter on Drugs and Therapeutics
- Collection of national and international Guidelines
- GPhA Generic Pharmaceutical Association
- Canada Generic Drugs: Government of Canada and Health Canada
Are Generic Drugs Less Safe than their Branded Equivalents?
What are generics drugs?
A generic drug is an identical, or bioequivalent, version of a branded drug made by another party. For approval of a generic, the drug company must submit an abbreviated new drug application (ANDA) to the Federal Drug Agency (FDA).
To gain FDA approval, a generic drug must:
- Contain the same active ingredients as the innovator drug (inactive ingredients may vary)
- Be identical in strength, dosage form, and route of administration
- Have the same use indications
- Be bioequivalent
- Meet the same batch requirements for identity, strength, purity, and quality
- Be manufactured under the same strict standards of FDA’s good manufacturing practice regulations required for innovator products
Why are generic drugs cheaper?
Generic drugs account for 89% of the prescriptions dispensed in the USA but only 27% of drug spending. Part of the reason that generics are able to be sold at such reduced prices is the lack of obligation that generic companies have to carry out the original exploratory clinical trials. The process of receiving market access for novel branded drugs is significantly more time and cost consuming. In large this is due to the rigorous clinical trials that new drugs are required to go through. The ANDA process does not require the drug company to repeat costly animal and human clinical trials on active ingredients or dosage forms that have already gained approval for safety and effectiveness.
Another benefit for generics is that they enter a market that already has an actively engaged customer base. Generic companies do not have to allocate extensive resources to marketing and advertisement, as the drug is already familiar to healthcare practitioners, prescribers and patients. Additionally, this pre-established customer base negates the requirement for a large sales force.
Are generics less safe?
In a nutshell, no. Generic drugs should be as safe as their branded equivalents. For example, different batches of branded drugs can often be metabolized differently by individuals, this tends to be of little medical significance. The same is expected and accepted for generic versions of branded drugs.
In accordance with FDA regulations, a generic drug’s maximum concentration of active ingredient in the blood must not fall more than 20% below or go 25% above that of the branded drug. This narrow range ensures that the generic will perform similarly to the branded drug. The time it takes the generic drug to reach the bloodstream in healthy volunteers is also monitored. This gives the bioavailability of the generic drug, which can be compared to that of the branded drug. In any given period of time, the amount of active ingredient delivered to the patient’s blood by the generic drug must be the same as that for the branded drug. Furthermore, generic manufacturing, packaging, and testing sites are held to the same quality standards as sites for brand name drugs are.
Despite proven bioequivalence and proven safety profiles, generic drugs are still sold at substantially lower prices than branded drugs. This results in a reduction of $3 billion per week on USA healthcare spending, and save consumers between $8 and $10 billion a year at retail pharmacies1, cementing the economic case
- SAVINGS An Economic Analysis of Generic Drug Usage in the U.S.. Generic Pharmaceutical Association, September 2011, page 1
5,864 total views, 50 views today